Across observational cohorts of periconceptional or first-trimester GLP-1RA exposure including liraglutide, hypertensive-disorder-of-pregnancy risk was not significantly associated with exposure versus no exposure (OR 0.91, CI 0.57-1.47).
In plain wordsAcross observational pregnancies with early GLP-1 exposure including liraglutide, pregnancy-hypertension risk did not differ significantly from no exposure.
- Peptide
- Liraglutide
- Outcome
- No significant changeHypertensive disorders of pregnancy risk
- Study
n = 10,880
- Comparator
- Unexposed
- Outcome group
- Pregnancy and fetal development · Reproductive and sexual health
Measurements
- Odds ratio
- 0.91
- hypertensive disorders of pregnancy; pooled GLP-1RA exposure versus unexposed; 95% CI 0.57-1.47
Source sentences
In the pooled analysis, GLP-1 RA exposure showed a HDP risk with an OR 0.91 (OR 0.91, CI 0.57-1.47) with no statistical significance.
6 context sentences(design, population, supporting numbers)
We performed a meta-analysis to investigating association between GLP-1 RAs preconception or first trimester of gestation exposure and HDP risk.
Cochrane Central Register of Controlled Trials databases, ClinicalTrials.gov, PubMed, Scopus, and EMBASE databases were searched from inception through December 15, 2025.
All eligible studies were observational cohorts.
We pooled odds ratios with 95% confidence intervals using a random-effects Mantel-Haenszel model.
Of 75 records identified, 3 retrospective cohort studies met inclusion criteria with 10,880 pregnancies (4942 exposed to GLP-1 RAs and 5938 unexposed).
All the studies were conducted in the United States between 2014-2025 and evaluated the semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, lixisenatide, and albiglutide exposure.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.